MarkLMosterMD
Neurology • Philadelphia, PANeuro-Ophthalmology
Professor of Neurology and Ophthalmology, Wills Eye Institute, Jefferson Medical College
Dr. Moster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
840 Walnut St
Ste 930
Philadelphia, PA 19107Phone+1 215-928-3130
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Neuro-Ophthalmology, 1983 - 1984
UPMC Medical Education (Pittsburgh)Residency, Neurology, 1980 - 1983- UPMC Medical EducationInternship, Internal Medicine, 1979 - 1980
SUNY Upstate Medical UniversityClass of 1979
Certifications & Licensure
FL State Medical License 2005 - 2026
NJ State Medical License 1989 - 2025
PA State Medical License 1980 - 2024- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Top MD Consumers Checkbook
Clinical Trials
- Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis Start of enrollment: 2013 Nov 01
- Electric Stimulation of the Eye to Improve Vision After Trauma Start of enrollment: 2013 Jul 01
- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Start of enrollment: 2013 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy.Nancy J Newman, Patrick Yu-Wai-Man, Prem S Subramanian, Mark L Moster, An-Guor Wang
Brain. 2023-04-19 - 72 citationsGadolinium-DTPA-enhanced magnetic resonance imaging in optic neuropathies.John Guy, Anthony A. Mancuso, Ronald G. Quisling, Roy W. Beck, Mark L. Moster
Ophthalmology. 1990-05-01 - 188 citationsLatanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.Carl B. Camras, Albert Alm, Peter G. Watson, Johan Stjernschantz, H. Aasved
Ophthalmology. 1996-11-01
Press Mentions
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®August 31st, 2021
GenSight Biologics Reports Findings from REALITY Study and REVERSE-RESCUE Analysis Highlighting Positive Benefits from LUMEVOQ™ (GS010) Compared to LHON Natural HistoryDecember 11th, 2019
Literature CommentarySeptember 30th, 2019- Join now to see all
Grant Support
- Cerebral Cortical Mechanisms For Control Of SaccadesNational Institute Of Neurological Disorders And Stroke1990–1994
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
